CHANGING
THE GAME OF
3D BIOPRINTING.
OUR TECHNOLOGY
Glue4Life is a next-generation bioink platform for 3D bioprinting living tissues and organs.
TOWARDS CLINICAL USE
Glue4Life is biodegradable and manufactured using clinically compatible components, therefore holding great potential for future clinical applications of 3D bioprinted tissues.
CUSTOMIZABLE PLATFORM
The requirements of different human tissues vary and therefore, Glue4Life platform is customizable for different cell and tissue types.
BIOCOMPATIBILITY
Cell friendly crosslinking method - no cytotoxic components limiting cell survival and functionality during and after printing process. Glue4Life has shown excellent biocompatibility and tissue formation.
PRINTABILITY
Glue4Life offers printable hydrogels with shear-thinning properties resulting in excellent printability and printing quality even with small nozzle diameters.
SIMPLE PROCESS
The printing process of Glue4Life is simple - no additional crosslinking step is required.
ABOUT US
OUR VISION
Our vision is to shift the paradigm of 3D bioprinting by simplifying the printing process and improving maturation and functionality of the printed tissues.
We envision to advance the development of tissues and organs for future clinical applications by offering bioinks manufactured with clinically compatible components.
OUR TEAM
Our multidisciplinary team has over a combined 30 years of expertise in the fields of tissue engineering, polymer chemistry and development of off-the-shelf human stem cell therapies.
The team has extensive hands-on experience on 3D bioprinting technologies, including bioprinting of human stem cells.
OUR STORY
Glue4Life is a spin-off company developing next-generation bioink platform. We originate from the Faculty of Medicine and Health Technology at Tampere University, Finland.
We have always had a clinical mind-set with the focus on finding future solutions for patients in need. With Glue4Life, we convert this into 3D bioprinting.
OUR UNIQUENESS
The unique Glue4Life composition provides the elastic and glue-like properties of our bioink platform - hence the name!
Glue4Life is designed to be clinically compatible already from the start - no alginate, cellulose and animal-derived polymers used.
Bioprinted iPSC-derived neurons have high axonal growth within Glue4Life.
Bioprinted hUVECs form vascularized networks within Glue4Life.
The viability of hepatocytes is high in Glue4Life which also allows the cells to form clusters from single cells.
PUBLICATIONS
Where has Glue4Life been featured?
A. Mörö et al. Biofabrication. 2023.
Hyaluronic acid based next generation bioink for 3D bioprinting of human stem cell derived corneal stromal model with innervation
"The bioink showed excellent shear thinning property, viscosity, printability, shape fidelity and self-healing properties with high cytocompatibility."
P. Puistola et al. Materials Today Bio. 2024.
Novel strategy for multi-material 3D bioprinting of human stem cell based corneal stroma with heterogenous design
"The developed multi-material bioprinting strategy provides great potential as a biofabrication solution for manufacturing organized, heterogenous microstructures of native tissues."
Puistola et al. ACS Applied Materials & Interfaces. 2024.
Cornea-Specific Human Adipose Stem Cell-Derived Extracellular Matrix for Corneal Stroma Tissue Engineering
"Our previously developed hyaluronic acid -based bioink was used as the backbone and the decellularized hASC-CSK derived ECM as a bioink component to prepare a corneal stroma-specific bioink."
Grönroos et al. Stem Cell Research & Therapy. 2024.
Bioprinting of human pluripotent stem cell derived corneal endothelial cells with hydrazone crosslinked hyaluronic acid bioink
"By using our simple and directed differentiation protocol for hPSC-CEnCs and corneal endothelium specific bioink design, we successfully demonstrated high tissue integration of the cell containing bioink and proof-of-concept for the bioprinted natural corneal endothelium resembling structure."
NEWS AND EVENTS
01/04/2024
Glue4Life is preparing to spin out,
stay tuned!
The Research-to-Business project ended in March 2024. The team is now preparing to spin out from Tampere University. Stay tuned!
07/09/2023
Glue4Life wins the pitching competition at HealthBIO 2023!
Our commercial officer Paula Puistola pitched Glue4Life business case at HealthBIO 2023 Turku, and Glue4Life earned 1st place in the Pitching Competition. Congratulations for the recognition!
12/04/2023
Glue4Life earned 2nd place in TERMIS Americas Business Plan Competition!
Our commercial officer Paula Puistola pitched Glue4Life business case in the Business Plan Competition in TERMIS Americas 2023. Glue4Life earned 2nd place in the competition. Congratulations for the recognition!
10/10/2022
Glue4Life wins a pitch award in Nordic Innovation Fair!
Our project manager Anni Mörö pitched Glue4Life business case in front of an international panels of investors and experts at Nordic Innovation Fair in Copenhagen on 26 September. Glue4Life was one of the eight winners. Congratulations!
26/01/2024
Steering group acknowledges Glue4Life as one of the best lead R2B projects!
In the last steering group meeting of the Research-to-Business project, Glue4Life was acknowledged as "one of the best lead R2B projects". Accurate and well organized project management is important for us at Glue4Life so we are proud of the statement!
01/08/2023
Glue4Life collaborates
with Finnadvance!
Glue4Life is happy to announce a collaboration with Finnadvance! Finnadvance is a Finland-based organ-on-chip company that produces the AKITA microfluidic platform. It allows the modelling of vascularized tissues and organoid in a high throughput-compatible manner with a broad rang of application from PK/PD & toxicology to basic scientific research. Our collaboration explores the effect of Glue4Life’s bioink on vascularization in the AKITA plates.
11/01/2023
Glue4Life was selected
to SPARK Finland!
Glue4Life was selected as one of the new projects in SPARK Finland Spring 2023 batch. This helps our team to develop the Glue4Life business case and increase the maturity of our bioink discovery towards clinical solutions.
01/01/2022
Glue4Life granted 555 000€ funding by Business Finland!
Glue4Life team received major Research to business funding from Business Finland. The grant total is 550 000 €. Research to Business funding is intended for public research organizations for projects in which research groups and researchers aim to develop their research into new business and to commercialize their research results.